이 페이지의 번역은 실험적이며 개발 중입니다. 여러분의 환영합니다!

Apyx Medical 관리

관리 기준 확인 3/4

Apyx Medical's CEO는 Charlie Goodwin, Dec2017 에 임명되었습니다 의 임기는 6.5 년입니다. 총 연간 보상은 $ 1.26M, 38.2% 로 구성됩니다. 38.2% 급여 및 61.8% 보너스(회사 주식 및 옵션 포함). 는 $ 122.40K 가치에 해당하는 회사 주식의 0.26% 직접 소유합니다. 122.40K. 경영진과 이사회의 평균 재임 기간은 각각 5.4 년과 6.4 년입니다.

주요 정보

Charlie Goodwin

최고 경영자

US$1.3m

총 보상

CEO 급여 비율	38.2%
CEO 임기	6.5yrs
CEO 소유권	0.3%
경영진 평균 재임 기간	5.4yrs
이사회 평균 재임 기간	6.4yrs

최근 관리 업데이트

Recent updates

Is Apyx Medical (NASDAQ:APYX) Using Debt In A Risky Way?

Jun 19

Revenues Working Against Apyx Medical Corporation's (NASDAQ:APYX) Share Price Following 25% Dive

Apr 18

Apyx Medical Corporation (NASDAQ:APYX) Analysts Just Slashed This Year's Estimates

Mar 26

Take Care Before Diving Into The Deep End On Apyx Medical Corporation (NASDAQ:APYX)

Feb 16

Is Apyx Medical (NASDAQ:APYX) A Risky Investment?

Sep 14

Does Apyx Medical (NASDAQ:APYX) Have A Healthy Balance Sheet?

Jun 07

Forecast: Analysts Think Apyx Medical Corporation's (NASDAQ:APYX) Business Prospects Have Improved Drastically

Mar 21

Here's Why We're Watching Apyx Medical's (NASDAQ:APYX) Cash Burn Situation

Dec 14

We're Not Very Worried About Apyx Medical's (NASDAQ:APYX) Cash Burn Rate

Aug 30

Apyx Medical GAAP EPS of -$0.16 beats by $0.03, revenue of $10.3M misses by $0.26M

Aug 11

Apyx Medical gets FDA nod for Renuvion's use in improving loose skin on neck, chin

Jul 18

Companies Like Apyx Medical (NASDAQ:APYX) Are In A Position To Invest In Growth

May 26

Are Investors Undervaluing Apyx Medical Corporation (NASDAQ:APYX) By 42%?

Mar 15

CEO 보상 분석

Charlie Goodwin 의 보수는 Apyx Medical 의 수익과 비교하여 어떻게 변경되었나요?
날짜	총 보상	급여	회사 수익
Mar 31 2024	n/a	n/a	-US$23m
Dec 31 2023	US$1m	US$483k	-US$19m
Sep 30 2023	n/a	n/a	-US$15m
Jun 30 2023	n/a	n/a	-US$16m
Mar 31 2023	n/a	n/a	-US$21m
Dec 31 2022	US$2m	US$483k	-US$23m
Sep 30 2022	n/a	n/a	-US$19m
Jun 30 2022	n/a	n/a	-US$18m
Mar 31 2022	n/a	n/a	-US$16m
Dec 31 2021	US$2m	US$450k	-US$15m
Sep 30 2021	n/a	n/a	-US$15m
Jun 30 2021	n/a	n/a	-US$14m
Mar 31 2021	n/a	n/a	-US$15m
Dec 31 2020	US$2m	US$450k	-US$12m
Sep 30 2020	n/a	n/a	-US$16m
Jun 30 2020	n/a	n/a	-US$16m
Mar 31 2020	n/a	n/a	-US$16m
Dec 31 2019	US$2m	US$450k	-US$20m
Sep 30 2019	n/a	n/a	-US$18m
Jun 30 2019	n/a	n/a	-US$15m
Mar 31 2019	n/a	n/a	-US$14m
Dec 31 2018	US$1m	US$400k	-US$11m
Sep 30 2018	n/a	n/a	-US$10m
Jun 30 2018	n/a	n/a	-US$12m
Mar 31 2018	n/a	n/a	-US$15m
Dec 31 2017	US$2m	US$15k	-US$14m

보상 대 시장: Charlie 의 총 보상 ($USD 1.26M )은 US 시장( $USD 683.56K ).

보상과 수익: Charlie 의 보상은 지난 한 해 동안 회사 성과와 일치했습니다.

CEO

Charlie Goodwin (57 yo)

6.5yrs

테뉴어

US$1,261,470

보상

Mr. Charles D. Goodwin II, also known as Charlie, has been Chief Executive Officer and Director of Apyx Medical Corporation (formerly known as Bovie Medical Corporation) since December 15, 2017 and serves...

리더십 팀

이름	위치	테뉴어	보상	소유권
Charles Goodwin	President	6.5yrs	US$1.26m	0.26% $ 120.6k
Matthew Hill	CFO, Treasurer & Secretary	less than a year	US$445.95k	0.0072% $ 3.4k
Moshe Citronowicz	Senior Vice President	12.4yrs	US$538.31k	1.32% $ 611.7k
Todd Hornsby	Executive Vice President	5.4yrs	US$746.27k	0% $ 0
Stavros Vizirgianakis	Executive Chairman	less than a year	데이터 없음	5.04% $ 2.3m

5.4yrs

평균 재임 기간

55yo

평균 연령

경험이 풍부한 관리: APYX 의 관리팀은 노련하고 경험 (평균 재직 기간 5.4 년)입니다.

이사회 구성원

이름	위치	테뉴어	보상	소유권
Charles Goodwin	President	6.5yrs	US$1.26m	0.26% $ 120.6k
Stavros Vizirgianakis	Executive Chairman	less than a year	데이터 없음	5.04% $ 2.3m
Michael Geraghty	Independent Director	13.3yrs	US$114.06k	0.079% $ 36.9k
Lawrence Waldman	Lead Independent Director	13.3yrs	US$162.56k	0.12% $ 57.5k
Brian Kinney	Member of Medical Advisory Board	4.9yrs	데이터 없음	데이터 없음
Gregory Konesky	Member of Scientific Advisory Board	no data	US$9.30k	데이터 없음
Yuval Carmel	Member of Scientific Advisory Board	no data	데이터 없음	데이터 없음
John C. Andres	Independent Vice-Chairman of the Board	9.9yrs	US$144.06k	0% $ 0
Minnie Baylor-Henry	Independent Director	4.8yrs	US$116.56k	0% $ 0
Craig Swandal	Independent Director	6.3yrs	US$106.56k	0.22% $ 103.4k
Dennis Chi	Member of Medical Advisory Board	7.4yrs	데이터 없음	데이터 없음
Diane Duncan	Member of Medical Advisory Board	6.1yrs	데이터 없음	데이터 없음

6.4yrs

평균 재임 기간

68yo

평균 연령

경험이 풍부한 이사회: APYX 의 이사회는 경험(평균 재직 기간 6.4 년)으로 간주됩니다.

Apyx Medical 관리

관리 기준 확인 3/4

주요 정보

최근 관리 업데이트

Apyx Medical Corporation, Annual General Meeting, Aug 08, 2024

Apyx Medical Corporation, Annual General Meeting, Aug 08, 2024

Apyx Medical Corporation Appoints Matthew Hill as Chief Financial Officer, Effective December 4, 2023

Apyx Medical Corporation Announces Resignation of Tara Semb as Chief Financial Officer

Apyx Medical Corporation Announces Resignation of Tara Semb as Chief Financial Officer

President recently bought US$79k worth of stock

Recent updates

Apyx Medical Corporation, Annual General Meeting, Aug 08, 2024

Apyx Medical Corporation, Annual General Meeting, Aug 08, 2024

Is Apyx Medical (NASDAQ:APYX) Using Debt In A Risky Way?

First quarter 2024 earnings: Revenues exceed analysts expectations while EPS lags behind

Apyx Medical Corporation Reaffirms Earnings Guidance for the Full Year Ending December 31, 2024

New major risk - Revenue and earnings growth

Apyx Medical Corporation to Report Q1, 2024 Results on May 09, 2024

Revenues Working Against Apyx Medical Corporation's (NASDAQ:APYX) Share Price Following 25% Dive

Consensus revenue estimates fall by 17%

Apyx Medical Corporation (NASDAQ:APYX) Analysts Just Slashed This Year's Estimates

Apyx Medical Corporation Provides Earnings Guidance for the Year Ending December 31, 2024

Full year 2023 earnings: EPS misses analyst expectations

Apyx Medical Corporation to Report Q4, 2023 Results on Mar 21, 2024

Take Care Before Diving Into The Deep End On Apyx Medical Corporation (NASDAQ:APYX)

Apyx Medical Corporation Announces Peer-Reviewed Clinical Publication Evaluating the Safety of Renuvion® Following Liposuction in Multiple Areas of the Body

New major risk - Revenue and earnings growth

Apyx Medical Corporation Provides Preliminary Revenue Guidance for the Fourth Quarter and Full Year Ended December 31, 2023

Apyx Medical Corporation Appoints Matthew Hill as Chief Financial Officer, Effective December 4, 2023

Apyx Medical Corporation Announces Resignation of Tara Semb as Chief Financial Officer

Apyx Medical Corporation Announces Resignation of Tara Semb as Chief Financial Officer

New major risk - Share price stability

President recently bought US$79k worth of stock

Consensus revenue estimates fall by 11%

Apyx Medical Corporation announced that it expects to receive $45 million in funding

Price target increased by 16% to US$9.00

New minor risk - Market cap size

Apyx Medical Corporation to Report Q3, 2023 Results on Nov 09, 2023

Is Apyx Medical (NASDAQ:APYX) A Risky Investment?

New major risk - Revenue and earnings growth

Second quarter 2023 earnings: EPS exceeds analyst expectations while revenues lag behind

Apyx Medical Corporation Reaffirms Financial Guidance for the Year Ending December 31, 2023

New major risk - Share price stability

Executive Vice President exercised options and sold US$87k worth of stock

Apyx Medical Corporation to Report Q2, 2023 Results on Aug 10, 2023

Executive Vice President notifies of intention to sell stock

Apyx Medical Corporation, Annual General Meeting, Aug 10, 2023

Apyx Medical Corporation Announces FDA 510(k) Clearance for the Renuvion® Micro Handpiece

Does Apyx Medical (NASDAQ:APYX) Have A Healthy Balance Sheet?

Consensus estimates of losses per share improve by 15%

Price target increased by 33% to US$8.00

Apyx Medical Corporation Updates Earnings Guidance for the Year Ending December 31, 2023

First quarter 2023 earnings: EPS and revenues exceed analyst expectations

Consensus revenue estimates increase by 11%

Forecast: Analysts Think Apyx Medical Corporation's (NASDAQ:APYX) Business Prospects Have Improved Drastically

Full year 2022 earnings: EPS misses analyst expectations

Apyx Medical Corporation to Report Q4, 2022 Results on Mar 16, 2023

Apyx Medical Corporation Announces FDA 510(K) Submission for the Use of the Renuvion® Apr. Handpiece for the Coagulation of Subcutaneous Soft Tissues Where Needed, Following Liposuction

Apyx Medical Corporation Launches New 'Apyx One Console' for Cosmetic Surgical Procedures in the United States

Apyx Medical Corporation Provides Revenue Guidance for the Fourth Quarter and Full Year 2022

Here's Why We're Watching Apyx Medical's (NASDAQ:APYX) Cash Burn Situation

Consensus revenue estimates fall by 15%

Third quarter 2022 earnings: EPS and revenues miss analyst expectations

Insufficient new directors

Price target decreased to US$10.33

Apyx Medical Corporation Updates Earnings Guidance for the Year Ending December 31, 2022

Apyx Medical Corporation to Report Q3, 2022 Results on Nov 10, 2022

Insufficient new directors

President recently bought US$70k worth of stock

We're Not Very Worried About Apyx Medical's (NASDAQ:APYX) Cash Burn Rate

Price target increased to US$14.00

Second quarter 2022 earnings: EPS exceeds analyst expectations while revenues lag behind

Apyx Medical Corporation Updates Earnings Guidance for the Full Year Ending December 31, 2022

Apyx Medical GAAP EPS of -$0.16 beats by $0.03, revenue of $10.3M misses by $0.26M

Price target increased to US$12.50

Glancy Prongay & Murray LLP Reminds Investors of Looming Deadline in the Class Action Lawsuit Against Apyx Medical Corporation

Apyx Medical gets FDA nod for Renuvion's use in improving loose skin on neck, chin

Lead Independent Director exercised options to buy US$150k worth of stock.

Apyx Medical Corporation Announces Results of the U.S. Ide Clinical Study Evaluating the Use of Renuvion to Improve the Appearance of Lax Skin in the Neck and Submental Region

Apyx Medical Corporation to Report Q2, 2022 Results on Aug 11, 2022